Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 plus bevacizumab versus bevacizumab as first-line maintenance for epithelial ovarian cancer
ChiCTR2600133918Phase 3Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab rezetecan and bevacizumab in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecanbevacizumab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2600133918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133918.